Today: 19 April 2026
Unilever stock slips again in London as defensives lag record Europe rally
6 January 2026
1 min read

Unilever stock slips again in London as defensives lag record Europe rally

London, Jan 6, 2026, 08:30 GMT — Regular session

  • Unilever shares slip in early London trade after a broad selloff in defensive staples
  • Investors rotate into defence and tech as European benchmarks hover at record levels
  • Unilever’s next catalyst is its full-year results in February

Unilever (ULVR.L) was down 29 pence, or 0.6%, at 4,670 pence by 0815 GMT, after opening at 4,681. The stock traded between 4,658 and 4,682 pence, extending Monday’s 2.6% fall to 4,699.

The slide matters because it has come alongside a risk-on push in Europe that has left consumer staples behind. On Monday, Unilever and Nestle fell nearly 3% each as investors piled into defence and technology shares, lifting the STOXX 600 above the 600-point mark for the first time, Reuters reported.

In London, the FTSE 100 closed up 0.5% at 10,004.57 — its first close above 10,000 — supported by gains in precious-metal miners and defence stocks after the Venezuela headlines, according to Reuters.

Unilever is typically seen as a defensive stock, meaning demand for its everyday products tends to hold up even when growth slows. That steadiness can turn into a drag when investors favour higher-beta sectors that move more sharply with the economic outlook.

The company is also still being priced through the December demerger of its ice-cream arm, The Magnum Ice Cream Company, a restructuring designed to simplify a business with a cold-chain-heavy supply network. “For the underlying Unilever business, ice cream has been a drag on volumes,” Edward Lewis, an analyst at Rothschild & Co Redburn, told Reuters; Unilever has said it expects operating margins — operating profit as a share of sales — to be 100 basis points higher without ice cream in the second half, to at least 19.5% (a basis point is 0.01 percentage point). Reuters

From a chart perspective, the shares are sitting just above last year’s low and well below the spring high — levels that can harden into support and resistance when momentum fades.

Macro traders are looking to Friday’s U.S. jobs report for direction on rate-cut expectations, after the dollar pulled back and global equities kept a record run going, a Reuters market report said.

Investors are also watching for evidence that Unilever can translate its post-demerger focus into faster volume-led growth, while keeping pricing disciplined. Any shift in promotional intensity in key markets would be read as a clue on how competitive conditions are evolving.

Deal appetite remains another watchpoint. Chief executive Fernando Fernandez said in December the group planned to allocate about 1.5 billion euros a year for mergers and acquisitions, with a heavy focus on the United States.

But the defensive selloff is not a one-way trade. A wobble in risk sentiment can quickly send money back into staples, while a soft read on volumes would sharpen scrutiny on whether the post-ice-cream margin uplift can hold.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Freeport-McMoRan stock jumps near 52-week high as copper hits record — what to watch next
Previous Story

Freeport-McMoRan stock jumps near 52-week high as copper hits record — what to watch next

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms
Next Story

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms

Go toTop